Logo for Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Investor Relations Material

Latest events

Logo for Corbus Pharmaceuticals Holdings

Q1 2025

6 May, 2025
Logo for Corbus Pharmaceuticals Holdings

Q4 2024

11 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Corbus Pharmaceuticals Holdings Inc

Access all reports
Corbus Pharmaceuticals Holdings Inc. is a biopharmaceutical company that specializes in precision oncology. The company's research and development efforts focus on innovative treatments that target well-understood biological pathways related to cancer. Corbus' pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) designed to target the Nectin-4 protein on cancer cells, and CRB-601, an anti-integrin monoclonal antibody that inhibits the activation of TGFβ on cancer cells. These treatments are intended to combat serious illnesses by offering new therapeutic options for patients. The company is headquartered in Norwood, Massachusetts, and its shares are listed on the NASDAQ.